Skip to main content

31.03.2017 | Case report

Acquired factor V deficiency following transcatheter arterial chemoembolization for hepatocellular carcinoma: a case report

verfasst von: Taishi Yamane, Katsunori Imai, Mitsuhiro Uchiba, Naoki Umezaki, Takanobu Yamao, Takayoshi Kaida, Shigeki Nakagawa, Daisuke Hashimoto, Yo-ichi Yamashita, Akira Chikamoto, Naoya Yoshida, Hideo Baba

Erschienen in: International Cancer Conference Journal | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Acquired factor V deficiency is a rare condition associated with a wide variety of causes. We herein report the case of a 75-year-old man who developed acquired factor V deficiency associated with gastrointestinal bleeding after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma. Laboratory data revealed prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT) and a significant reduction in the factor V (FV) activity. Infusion of fresh-frozen plasma (FFP) was unable to correct the prolonged PT and APTT. Four weeks after onset, his coagulation parameters improved spontaneously with no particular treatment. The patient developed acquired FV deficiency after TACE treatment using cisplatin, and thus, cisplatin was suspected as the cause of this coagulopathy. If coagulopathy that is not corrected by FFP transfusion after TACE is observed, acquired factor V deficiency, although extremely rare, should be considered.
Literatur
1.
Zurück zum Zitat Ortel TL (1999) Clinical and laboratory manifestations of anti-factor V antibodies. J Lab Clin Med 133:326–334CrossRefPubMed Ortel TL (1999) Clinical and laboratory manifestations of anti-factor V antibodies. J Lab Clin Med 133:326–334CrossRefPubMed
2.
Zurück zum Zitat Tracy PB, Eide LL, Bowie EJ et al (1982) Radioimmunoassay of factor V in human plasma and platelets. Blood 60:59–63PubMed Tracy PB, Eide LL, Bowie EJ et al (1982) Radioimmunoassay of factor V in human plasma and platelets. Blood 60:59–63PubMed
3.
Zurück zum Zitat Streiff MB, Ness PM (2002) Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 42:18–26CrossRefPubMed Streiff MB, Ness PM (2002) Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 42:18–26CrossRefPubMed
4.
Zurück zum Zitat Knobl P, Lechner K (1998) Acquired factor V inhibitors. Baillieres Clin Haematol 11:305–318CrossRefPubMed Knobl P, Lechner K (1998) Acquired factor V inhibitors. Baillieres Clin Haematol 11:305–318CrossRefPubMed
5.
Zurück zum Zitat Franchini M, Lippi G (2011) Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis 31:449–457CrossRefPubMed Franchini M, Lippi G (2011) Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis 31:449–457CrossRefPubMed
6.
Zurück zum Zitat Franchini M, Gandini G, Di Paolantonio T et al (2005) Acquired hemophilia A: a concise review. Am J Hematol 80:55–63CrossRefPubMed Franchini M, Gandini G, Di Paolantonio T et al (2005) Acquired hemophilia A: a concise review. Am J Hematol 80:55–63CrossRefPubMed
7.
Zurück zum Zitat Ang AL, Kuperan P, Ng CH et al (2009) Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 101:852–859PubMed Ang AL, Kuperan P, Ng CH et al (2009) Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 101:852–859PubMed
8.
Zurück zum Zitat Wang X, Qin X, Yu Y, Wang R, et al. (2016) Acquired factor V deficiency in a patient with a urinary tract infection presenting with haematuria followed by multiple haemorrhages with an extremely low level of factor V inhibitor: a case report and review of the literature. Blood Coagul Fibrinolysis (in press) doi:10.1097/MBC.0000000000000581 Wang X, Qin X, Yu Y, Wang R, et al. (2016) Acquired factor V deficiency in a patient with a urinary tract infection presenting with haematuria followed by multiple haemorrhages with an extremely low level of factor V inhibitor: a case report and review of the literature. Blood Coagul Fibrinolysis (in press) doi:10.​1097/​MBC.​0000000000000581​
Metadaten
Titel
Acquired factor V deficiency following transcatheter arterial chemoembolization for hepatocellular carcinoma: a case report
verfasst von
Taishi Yamane
Katsunori Imai
Mitsuhiro Uchiba
Naoki Umezaki
Takanobu Yamao
Takayoshi Kaida
Shigeki Nakagawa
Daisuke Hashimoto
Yo-ichi Yamashita
Akira Chikamoto
Naoya Yoshida
Hideo Baba
Publikationsdatum
31.03.2017
Verlag
Springer Japan
Erschienen in
International Cancer Conference Journal / Ausgabe 3/2017
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-017-0290-1

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.